ARTICLE | Clinical News
Omarigliptin regulatory update
December 8, 2014 8:00 AM UTC
Merck submitted an NDA in Japan for omarigliptin to treat Type II diabetes. It is the first regulatory submission for the once-weekly oral dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitor. Merck expe...